智通财经APP获悉，阿斯利康 (AZN.US)和第一三共已自愿撤回在欧盟提交的datopotamab deruxtecan（ Dato-DXd ，德曲妥珠单抗）用于治疗局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者的上市许可申请（MAA）。

Preliminary results from TROPION-Lung05 reported at the main ESMO congress last year revealed an overall response rate (ORR) ...

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not ...